KLBF Stock Overview
Develops, manufactures, and trades in pharmaceutical products in Indonesia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for KLBF from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
PT Kalbe Farma Tbk. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp1,515.00 |
| 52 Week High | Rp1,795.00 |
| 52 Week Low | Rp985.00 |
| Beta | 0.044 |
| 1 Month Change | 15.21% |
| 3 Month Change | 36.49% |
| 1 Year Change | 1.68% |
| 3 Year Change | -5.31% |
| 5 Year Change | 7.45% |
| Change since IPO | 12,986.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| KLBF | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | 3.8% | 2.1% | -1.1% |
| 1Y | 1.7% | 5.5% | 2.8% |
Return vs Industry: KLBF underperformed the ID Pharmaceuticals industry which returned 5.5% over the past year.
Return vs Market: KLBF underperformed the ID Market which returned 2.8% over the past year.
Price Volatility
| KLBF volatility | |
|---|---|
| KLBF Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in ID Market | 14.0% |
| 10% least volatile stocks in ID Market | 3.6% |
Stable Share Price: KLBF has not had significant price volatility in the past 3 months compared to the ID market.
Volatility Over Time: KLBF's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 12,841 | Bernadette Ruth Setiady | www.kalbe.co.id |
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic divisions. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products.
PT Kalbe Farma Tbk. Fundamentals Summary
| KLBF fundamental statistics | |
|---|---|
| Market cap | Rp69.06t |
| Earnings (TTM) | Rp3.36t |
| Revenue (TTM) | Rp33.11t |
Is KLBF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KLBF income statement (TTM) | |
|---|---|
| Revenue | Rp33.11t |
| Cost of Revenue | Rp20.05t |
| Gross Profit | Rp13.06t |
| Other Expenses | Rp9.70t |
| Earnings | Rp3.36t |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 73.71 |
| Gross Margin | 39.46% |
| Net Profit Margin | 10.15% |
| Debt/Equity Ratio | 1.9% |
How did KLBF perform over the long term?
See historical performance and comparisonDividends
Does KLBF pay a reliable dividends?
See KLBF dividend history and benchmarks| Kalbe Farma dividend dates | |
|---|---|
| Ex Dividend Date | Jun 04 2025 |
| Dividend Pay Date | Jun 25 2025 |
| Days until Ex dividend | 3 days |
| Days until Dividend pay date | 24 days |
Does KLBF pay a reliable dividends?
See KLBF dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/01 02:08 |
| End of Day Share Price | 2025/05/28 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PT Kalbe Farma Tbk. is covered by 33 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Helmy Kristanto | BNP Paribas Securities (Asia) |
| Swati Chopra | BofA Global Research |
| Jason Chandra | CGS International |